BIOSYENT INC (RX.CA) Stock Price, Quote, News and Overview
TSX-V:RX - TSX Venture Exchange - CA0906901081 - Common Stock - Currency: CAD
RX.CA Quote, Performance and Key Statistics
TSX-V:RX (5/9/2025, 7:00:00 PM)
10.85
-0.15 (-1.36%)
The current stock price of RX.CA is 10.85 CAD. In the past month the price increased by 8.5%. In the past year, price increased by 27.65%.
RX.CA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| BHC.CA | BAUSCH HEALTH COS INC | 1.22 | 2.36B | ||
| CRON.CA | CRONOS GROUP INC | 15.33 | 1.06B | ||
| DHT-UN.CA | DRI HEALTHCARE TRUST | 5.69 | 695.43M | ||
| TLRY.CA | TILRAY BRANDS INC | N/A | 605.06M | ||
| GUD.CA | KNIGHT THERAPEUTICS INC | 114.2 | 567.86M | ||
| WEED.CA | CANOPY GROWTH CORP | N/A | 382.44M | ||
| ACB.CA | AURORA CANNABIS INC | 29.3 | 369.76M | ||
| CPH.CA | CIPHER PHARMACEUTICALS INC | 21.73 | 356.37M | ||
| HITI.CA | HIGH TIDE INC | N/A | 271.15M | ||
| NGEN.CA | NERVGEN PHARMA CORP | N/A | 252.15M | ||
| OGI.CA | ORGANIGRAM GLOBAL INC | N/A | 219.40M | ||
| TSND.CA | TERRASCEND CORP | N/A | 178.25M |
Related stock screener links
About RX.CA
Company Profile
BioSyent, Inc. is a specialty pharmaceutical company, which engages in the development of pharmaceutical and healthcare products. The company is headquartered in Mississauga, Ontario. The Company, through its wholly owned subsidiaries, BioSyent Pharma Inc., and BioSyent Pharma International Inc., acquires or licenses and develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary operates the Company’s business marketing biologically and health friendly non-chemical insecticides. Its products include Combogesic, Cathejell, FeraMAX Pd Therapeutic 150, FeraMAX Pd Maintenance 45, FeraMAX Pd Powder 15, Gelclair, Inofolic, Proktis-M, RepaGyn, and Tibella. Combogesic is for the short-term management of mild to moderate acute pain and the reduction of fever in adults. Cathejell combines sterile gel and 2% lidocaine jelly in a collapsible syringe that is ready to use. FeraMAX Pd Therapeutic 150 is an oral hematinic that helps the body form red blood cells and is indicated for the treatment of iron deficiency anemia.
Company Info
BIOSYENT INC
2476 Argentia Road, Suite 402
Mississauga ONTARIO L5N 6M1 CA
CEO: Rene Goehrum
Employees: 0
Phone: 18884390013
BIOSYENT INC / RX.CA FAQ
What is the stock price of BIOSYENT INC today?
The current stock price of RX.CA is 10.85 CAD. The price decreased by -1.36% in the last trading session.
What is the ticker symbol for BIOSYENT INC stock?
The exchange symbol of BIOSYENT INC is RX and it is listed on the TSX Venture Exchange exchange.
On which exchange is RX.CA stock listed?
RX.CA stock is listed on the TSX Venture Exchange exchange.
What is the price forecast or stock price prediction for BIOSYENT INC stock?
7 analysts have analysed RX.CA and the average price target is 11.99 CAD. This implies a price increase of 10.46% is expected in the next year compared to the current price of 10.85. Check the BIOSYENT INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BIOSYENT INC worth?
BIOSYENT INC (RX.CA) has a market capitalization of 124.45M CAD. This makes RX.CA a Micro Cap stock.
How many employees does BIOSYENT INC have?
BIOSYENT INC (RX.CA) currently has 0 employees.
What are the support and resistance levels for BIOSYENT INC (RX.CA) stock?
BIOSYENT INC (RX.CA) has a support level at 10.81 and a resistance level at 10.9. Check the full technical report for a detailed analysis of RX.CA support and resistance levels.
Is BIOSYENT INC (RX.CA) expected to grow?
The Revenue of BIOSYENT INC (RX.CA) is expected to grow by 17.23% in the next year. Check the estimates tab for more information on the RX.CA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy BIOSYENT INC (RX.CA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of RX.CA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of RX.CA, evaluating the profitability, health, valuation and growth aspects
- BIOSYENT INC (RX.CA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BIOSYENT INC (RX.CA) Sales and EPS estimates to see what analysts future expectations are.
- BIOSYENT INC (RX.CA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BIOSYENT INC (RX.CA) Insider and Institutional Ownership to learn about the owners and their transactions.
- BIOSYENT INC (RX.CA) Stock Chart to make your own analysis
- BIOSYENT INC (RX.CA) Latest news and press-releases to stay up to date.
Does BIOSYENT INC (RX.CA) stock pay dividends?
BIOSYENT INC (RX.CA) has a dividend yield of 1.71%. The yearly dividend amount is currently 0.18. Check the full fundamental report for a detailed analysis of RX.CA dividend history, reliability and sustainability.
When does BIOSYENT INC (RX.CA) report earnings?
BIOSYENT INC (RX.CA) will report earnings on 2025-05-23.
What is the Price/Earnings (PE) ratio of BIOSYENT INC (RX.CA)?
The PE ratio for BIOSYENT INC (RX.CA) is 17.5. This is based on the reported non-GAAP earnings per share of 0.62 and the current share price of 10.85 CAD. Check the full fundamental report for a full analysis of the valuation metrics for RX.CA.
RX.CA Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to RX.CA. When comparing the yearly performance of all stocks, RX.CA is one of the better performing stocks in the market, outperforming 77.7% of all stocks.
RX.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 8 / 10 to RX.CA. RX.CA gets an excellent profitability rating and is at the same time showing great financial health properties.
RX.CA Financial Highlights
Over the last trailing twelve months RX.CA reported a non-GAAP Earnings per Share(EPS) of 0.62. The EPS increased by 15.83% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 20.75% | ||
| ROA | 17.58% | ||
| ROE | 20.77% | ||
| Debt/Equity | 0.02 |
RX.CA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to RX.CA. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 32.4% and a revenue growth 17.23% for RX.CA